Oncology and Hematology

129-144 of 175

• 

  RestartResume

  Application of guidelines-recommended broad molecular profiling to patients with NSCLC

  RestartResume

  Application of guidelines-recommended broad molecular profiling to patients with NSCLC

  MinuteCE®

  Application of guidelines-recommended broad molecular profiling to patients with NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  RestartResume

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  MinuteCE®

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  RestartResume

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  MinuteCE®

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC

  RestartResume

  Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC

  MinuteCE®

  Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies

  RestartResume

  Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies

  MinuteCE®

  Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC

  RestartResume

  Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC

  MinuteCE®

  Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies

  RestartResume

  Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies

  MinuteCE®

  Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings

  RestartResume

  Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings

  MinuteCE®

  Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC

  RestartResume

  Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC

  MinuteCE®

  Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in NSCLC

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in NSCLC

  MinuteCE®

  Insights from global key opinion leaders on optimizing patient care in NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer

  RestartResume

  SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer

  Oncology and Hematology

  SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer

• 

  RestartResume

  TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1 

  RestartResume

  TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1 

  Oncology and Hematology

  TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1 

• 

  RestartResume

  Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer 

  RestartResume

  Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer 

  Oncology and Hematology

  Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer 

• 

  RestartResume

  TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer

  RestartResume

  TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer

  Oncology and Hematology

  TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer

• 

  RestartResume

  Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer 

  RestartResume

  Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer 

  Oncology and Hematology

  Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer 

• 

  RestartResume

  Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer

  RestartResume

  Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer

  Oncology and Hematology

  Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer

• Previous
• 1
• 2
• …
• 7
• 8
• 9
• 10
• 11
• Next